Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00502827 · ClinicalTrials.gov registry record · NA

Smoking Cessation for HIV/AIDS Patients

A NA study of Human Immunodeficiency Virus, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
NA
Development phase
706
Enrollment target
2
Study locations

NCT00502827: Completed NA study of Human Immunodeficiency Virus, sponsored by M.D. Anderson Cancer Center.

NCT00502827 is a NA study of Human Immunodeficiency Virus that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 706 participants, above the 166-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (325% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00502827, a NA study of Human Immunodeficiency Virus, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
NA
Development phase
706 participants
Enrollment target
2
Study locations

Study Summary

The goal of this research study is to look at treatments that may help individuals who have HIV/AIDS to stop smoking.

Interventions

  • BEHAVIORAL Cell Phone Intervention
  • OTHER Recommended Standard of Care

Study Locations (2)

Texas

  • Thomas Street Clinic - Houston
  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 706 participants
Start Date 2004-01
Est. Completion 2015-04
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00502827 record still lists

NCT00502827 is an interventional study that assigns participants to a tested intervention. The registered 706 participants enrollment target is mid-sized for trials with a published cap, above the 166-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (325% higher).

The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 2 interventions - of which Cell Phone Intervention is the first listed.

NCT00502827 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00502827 about?

NCT00502827 is a clinical study titled "Smoking Cessation for HIV/AIDS Patients". The goal of this research study is to look at treatments that may help individuals who have HIV/AIDS to stop smoking.

What is the current status of trial NCT00502827?

This trial is currently completed. It is a NA study. The enrollment target is 706 participants. The study started on 2004-01. Estimated completion is 2015-04.

What conditions does trial NCT00502827 study?

This clinical trial studies the following conditions: Human Immunodeficiency Virus.

What interventions are being tested in trial NCT00502827?

The interventions under investigation include: Cell Phone Intervention (BEHAVIORAL), Recommended Standard of Care (OTHER).

Who is sponsoring clinical trial NCT00502827?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00502827 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Human Immunodeficiency Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00502827's enrollment target sits among peer trials

706 4th of 39 higher than 36 of 39 other Human Immunodeficiency Virus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06480383 · 705 participants · Phase 2

    Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

  • NCT07067463 · 705 participants · Phase 3

    A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  • NCT05796687 · 704 participants · NA

    Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings

  • NCT06350734 · 704 participants

    Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00502827, the US trial registry maintained by the National Library of Medicine. NCT00502827 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.